A technically simple and rapid two-site immunoradiometric assay (IRMA) for human ACTH, based on monoclonal antibodies (MAbs), was compared with a clinically validated ACTH radioimmunoassay (RIA). Both methods measure ACTH 1-39 in unextracted plasma and cross-react <0·5% with ACTH fragments. ACTH levels were assessed in 103 patient samples: for concentrations in the range 5'3-1000
ng/L, results by the two methods were significantly correlated (r =0,82, n = 86, P< 0'001). The IRMA was more sensitive and had a wider working range than the RIA (detection limits 5·3 ng/L (IRMA) vs 11 ng/L (RIA); CV < 10% between 19 and 1000 ng/L (IRMA) and CV < 15% between 30 and 400 ng/L (RIA». In two patients for whom discrepant results were obtained, measurement of ACTH by bioassay and ACTH precursors by direct IRMA demonstrated the greater accuracy of the ACTH IRMA result. The improved performance of the IRMA combined with its many practical advantages compared to RIA, make it ideal for use in detailed clinical and physiological studies which have previously been hampered by the poor reliability of ACTH measurement.
The measurement of ACTH by radioimmunoassay (RIA) has proved difficult due mainly to the rarity and expense of high avidity antisera.P the difficulties associated with reliably producing a high quality radioligand and the low levels of circulating ACTH in normal subjects. These difficulties have previously been addressed by the use of extraction procedures to increase the concentration of ACTH prior to measurementv' and by increasing incubation times in the assay.5.6 However, these adaptations have made the measurement of ACTH technically demanding, imprecise and slow. In 1984, Nicholson et al? described a relatively simple and reliable RIA with the necessary sensitivity to detect normal levels of ACTH in unextracted human plasma. The polyclonal antiserum used in the assay recognizes ACTH 1-39 and the ACTH precursors, pro-opiomelanocortin (POMC) and pro-ACTH, but cross-reacts < O' 5% with structurally and/or biosynthetically related hormones (exmelanocyte stimulating hormone (ex-MSH), plipotrophic hormone (P-LPH) and p-endorphin (P-EP» which may be present in plasma.
For the measurement of other hormones two-Correspondence: Dr A White. 500 site immunoradiometric assays (IRMAs) have proved to be more robust, sensitive, precise and rapid than competitive immunoassays.P We have used monoclonal antibodies (MAbs) specific for ACTH residues 10-18 and ACTH 24--39 9 Laboratory reference ranges were based on plasma ACTH levels measured in 33 normal subjects at 0900 h. The ranges calculated (mean±2'5 x SD) were between 5 and 51 ng/L and II and 100 ng/L ACTH for the IRMA and the RIA, respectively.
PATIENTS AND SAMPLES
A total of 103 samples were collected from 30 patients with putative disorders of the hypothalamic-pituitary-adrenal axis (13 male, 17 female, mean age 48±18 years) ( Table 4 ). Of these 30 patients, nine had undergone an insulin tolerance test (ITT) and seven a glucagon stimulation test (GST), as part of their routine pituitary assessment. ACTH levels were therefore measured in 37 basal samples and 66 stimulated samples using both assays. Blood was collected into Iithiumheparin tubes and plasma separated within 30 min. Aliquots were stored in polystyrene tubes at -70°C prior to assay. The stability of endogenous immunoactive ACTH in whole blood and plasma has been assessed previously. I I A separate aliquot of each sample collected under identical conditions was used for each of the two assays.
DATA ANALYSIS
The detection limits of the two assays were calculated from the results of patient samples with low ACTH as described by Fraser and Wilde." Precision profiles were calculated using paired duplicate analysis. 14 The within-assay precision profiles were based on the results of 103 patient samples: between-assay precision profiles were based on the results obtained for quality control samples in the two assays. Regression coefficients were calculated by Deming's method as described by Payne."
Results

COMPARISON OF ASSAY PERFORMANCE
Mean standard curves for the IRMA (n=4) and the RIA (n = 5) are shown in Fig. I . In the two-site IRMA, the mean responses at 1000 ng/L and ong/L ACTH were 8300 cpm and 93 cpm, respectively, giving a signal to background ratio of 89: I. A doubling of counts was achieved by 8·3 ng/L ACTH. In the RIA, the mean maximal binding of 125I-ACTH was 22% with a mean nonspecific binding of 1·3%. Ten per cent of the labelled tracer was displaced (ED 10) by 15 ng/L ACTH, 50% (ED50) by 75 ng/L ACTH and 80% (ED80) by 310 ng/L ACTH. The mean detection limits for the IRMA and the RIA calculated using low ACTH levels" were 5·3 ng/L (n=4) and II ng/L (n=5) respectively. Mean within-assay precision profiles for the IRMA (n = 4) and the RIA (n = 5) based on 103 patient samples are shown in Fig. I . The withinassay coefficient of variation (CV) was < 10% between 19 ng/L and 1000 ng/L for the ACTH IRMA and < 15% between 30 ng/L and 400 ng/L for the RIA. Between-assay coefficients of variation based on the results of quality control samples were between 2·7 and 12% within the range 31-1146 ng/L for the IRMA (n=4) and between 7·3 and 24% in the range 40-165 ng/L for the RIA (n = 5) ( Table 2) . Over a longer period of 6 months, the coefficients of variation for QC samples in the IRMA with mean ACTH values of 26,5, 111,558 and 1104 ng/L were 8'5%, 10,3%, 7·8% and 7'4%, respectively (n = 52). In comparison, during the same period, the coefficients of variation for QC samples in the RIA with mean ACTH values of41, 72 and 144 ng/L were 18,6%, 10·1% and 12·0%, respectively (n = 10). Fewer ACTH RIAs were performed at this time due to use of the assay for routine ACTH measurements only. PARALLELISM ACTH levels for the majority of patient samples measured in the RIA diluted in parallel with the ACTH standard. In five patients with differing clinical disorders, plasma ACTH levels by RIA calculated using the results of diluted samples were inconsistent with those measured directly, with all samples from an individual patient following this trend in the assay ( Table 3) . Parallelism of patient samples in the IRMA has been confirmed in a previous study in which 12 specimens containing elevated levels of endogenous ACTH (60-328 ng/L) were shown to dilute in parallel with the standard curve. I I
CORRELA nON BETWEEN ACTH LEVELS
MEASURED IN THE IRMA AND THE RIA
The ACTH levelsin six samples from two patients were markedly elevated compared to the remainder of those in the study (1545-3320 ng/L and 880-7200 ng/L for the IRMA and RIA, respectively). These results were therefore excluded from the calculation of the correlation coefficient. In addition, samples containing ACTH levels below the detection limit of either assay were also excluded from the statistical analysis (n = II, five patients). For patient samples containing ACTH concentrations of < 1000 a Results other than those less than assay sensitivity have been corrected for dilution.
lIT, insulin tolerance test (0'2 U/kg intravenously).
GST, glucagon stimulation test (I mg subcutaneously). consistent with clinical information. However, the ACTH results for two patients were markedly discordant between the two assays. In patient JO, with Addison's disease (Fig. 2) (Table 4 ) Four patients had ACTH levels which were undetectable in the RIA but measurable in the IRMA (ACTH concentrations between 10 and 28 ng/L), demonstrating the greater sensitivity of the latter assay. A strong statistical correlation was obtained for ACTH levels measured by the two methods and in general patient results were ng/L a highly significant correlation between the two methods was obtained (r=0'82, P<O·OOI, n= 86, y=0'868x+23'6, Fig. 2 ). Analysis of the data for basal levels alone also demonstrated a strong correlation between the IRMA and the RIA (r=0'83, P<O·OOI, n=30) . In contrast, a poorer correlation was obtained between the two methods for ACTH levels following insulin or glucagon stimulation (r = O' 54, P < 0·00 I, n = 56). This poor correlation is largely due to the ACTH results obtained for patient AF (Fig. 2 ). If the ACTH results of this patient are excluded, the correlation for stimulated ACTH levels is much improved (r=0'87, P<O'OOI, n=52). simultaneous plasma cortisol estimation of 317 nrnol/L was more consistent with the ACTH result obtained in the IRMA. In patient AF, previously treated surgica1ly for a TSH-secreting pituitary adenoma, peak ACTH levels during the ITT rose from a basal level of28 ng/L to a peak of 30 ng/L in the IRMA and from a basal level of 106 ng/L to a peak of 239 ng/L in the RIA. During this test, cortisol levels rose from a basal level of 149 nrnol/L to a peak of220 nmol/L, indicative of ACTH deficiency and consistent with the ACTH result in the IRMA. For patients JO and AF the elevated ACTH levels measured in the RIA diluted in para1lel with the ACTH standard.
Discussion
addition, the assay is technica1ly simple, has a large sample capacity and is readily completed in less than 24 h, a1l factors which enhance its appeal as an alternative method for ACTH measurement in the routine biochemistry laboratory. ACTH determination has also been complicated by the cross-reactivity of many polyclonal antisera with ACTH fragments which are not biologica1ly active. In this study, we have compared the ACTH IRMA with an RIA based on an antiserum which has <0·5% cross-reactivity with known circulating ACTH fragments.! The two-site IRMA routinely achieved a detection limit of 5·3 ng/L compared with II ng/L for the RIA and was more precise with working ranges between 19 and 1000 ng/L (CY < 10%) and 3Q-400 ng/L (CY < 15%), respectively. The extended working range ofthe IRMA a1lowedthe direct measurement of ACTH levels in the majority of patient samples (n=97). Where very elevated ACTH levels are expected the standard curve of the assay can be extended to cover concentrations up to 5000 ng/L." If preferred, samples containing high ACTH levels can be diluted in standard matrix: para1lelism of diluted plasma samples has been confirmed in a previous study.'! In the RIA, ACTH concentrations were determined directly and at a four-fold or higher dilution to bring levels within the working range and to enable assessment of para1lelism in the assay. As reported by other authors,' some patient samples generated competitive binding curves which were non-parallel with the standard. Non-para1lelism of patients' ACTH results using RIA methods is often attributed to the measurement of fragments, but since the antiserum employed has little cross-reactivity with fragments, interference of plasma proteins in the assay seems a more likely explanation. Plasma interference can be removed by the extraction of ACTH from samples using silicic acid prior to RIA. 2 In this comparison, we have demonstrated a significant correlation between ACTH levels measured in the IRMA and the RIA up to 1000 ng/L, ACTH levels were consistent with clinical and biochemical information in a1l except two patients. In these subjects, ACTH levels determined by RIA were IO-fold higher than those obtained in the IRMA and these levels diluted in para1lel with the standard curve. The RIA is specific for ACTH 1-39 and so it would be difficult to explain these observations in terms of measurement of ACTH fragments, or related peptides (melanotrophins or lipotrophins). For both of these patients ACTH levels measured Major difficulties of ACTH measurement relate to the rarity of high avidity antisera which can be used to detect levels in the physiological range. Consequently, reasonable assay sensitivity in ACTH RIAs can only be achieved by delayed addition oflabe1led antigen to the system, resulting in methods which are both time-consuming and technica1ly difficult. Other steps which have been taken to improve RIA performance include the repurification of 125I-ACTH by column chromatography prior to each assay and the execution of a1l assay procedures in ice-water baths.' The practical difficulties of such methods have limited ACTH measurement to a few specialised centres, although it has wide clinical and research applicability. The use of monoclonal antibodies in a two-site IRMA for ACTH ensures a reproducible supply of high quality reagents. In using an ACTH bioassay" were in good agreement with those obtained in the IRMA (20 ng/L vs 27 ng/L for patient AF and 65 ng/l, vs 55 ng/L for patient JO, in the bioassay and IRMA respectively). Further evidence that the ACTH result in the IRMA was the more appropriate was obtained when low cortisol levels were recorded for these patient samples. The discrepancies between the ACTH levels measured in these individuals may be explained by differences in the recognition of ACTH precursor peptides in the two assays. The formal cross-reactivities of the precursors in the RIA has not been documented due to the difficulty of obtaining pure peptides. However, the IRMA is thought to cross-react approximately I % with POMC and 10% with pro-ACTH. 16 Measurement of the precursors, POMC and pro-ACTH, using a unique two-site IRMAI7 revealed levels of 57 and 49 pmol/L for patients AF and JO respectively, suggesting that the discrepancies observed between ACTH levels in these patients may be due to higher crossreactivity of the less bioactive precursors in the ACTH RIA.
In conclusion, we have developed a two-site IRMA for ACTH which solves many of the practical problems associated with ACTH measurement. Results obtained for patient samples using the IRMA correlate well with those measured by RIA. In two patients for whom discordant results were recorded, the ACTH levels determined by IRMA were shown to be the more accurate on the basis of other biochemical findings. The increased accuracy and large sample capacity of this assay have enabled us to study fluctuations in ACTH levels in patients with disorders of the HPA axis, before and during appropriate treatment. Preliminary investigations indicate that there may be a role for frequent ACTH measurements in monitoring the effects of therapy in different clinical states. IS The improved sensitivity and reproducibility of the IRMA have enabled us to re-evaluate the usefulness of the GSTas a measure of pituitary ACTH reserve and to study the role of oxytocin in the modulation of adenohypophyseal function. 19.20 We conclude that the IRMA provides a practical and reliable alternative to RIA for routine ACTH measurement. The assay is also suitable for use in detailed studies which may further our understanding of ACTH in normal and abnormal physiology.
